Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes

Psychiatry Research

Volumn 188, Issue 3, 2011, Pages 310-314

  Sevy, Serge ^a,b,c,d   Robinson, Delbert G ^a,b,c,d   Sunday, Suzanne ^a,d   Napolitano, Barbara ^a   Miller, Rachel ^e   McCormack, Joanne ^b   Kane, John ^a,b,c,d  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Alcohol; Atypicals; Marijuana; Negative symptoms; Positive symptoms; Psychosis

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ANHEDONIA; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; MEDICAL HISTORY; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79960698546     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.05.001     Document Type: Article

References (24)

1. Akerele E., Levin F.R. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. American Journal of Addiction 2007, 16:260-268.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. British Journal of Psychiatry Suppl 1989, 49-58.
3. Barnes T.R., Mutsatsa S.H., Hutton S.B., Watt H.C., Joyce E.M. Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry 2006, 188:237-242.
4. Barnett J.H., Werners U., Secher S.M., Hill K.E., Brazil R., Masson K., Pernet D.E., Kirkbride J.B., Murray G.K., Bullmore E.T., Jones P.B. Substance use in a population-based clinic sample of people with first-episode psychosis. British Journal of Psychiatry 2007, 190:515-520.
5. Brunette M.F., Drake R.E., Xie H., McHugo G.J., Green A.I. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin 2006, 32:637-643.
6. Buhler B., Hambrecht M., Loffler W., an der Heiden W., Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research 2002, 54:243-251.
7. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
8. Cantwell R., Brewin J., Glazebrook C., Dalkin T., Fox R., Medley I., Harrison G. Prevalence of substance misuse in first-episode psychosis. British Journal of Psychiatry 1999, 174:150-153.
9. Drake R.E., Xie H., McHugo G.J., Green A.I. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin 2000, 26:441-449.
10. First M., Spitzer R., Gibbon M., Williams J. Structured Clinical Interview for Axis DSM-IV Disorders - Patient Edition 1998, New York State Psychiatric Institute, New York.
11. Green A.I., Burgess E.S., Dawson R., Zimmet S.V., Strous R.D. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia Research 2003, 60:81-85.
12. Hambrecht M., Hafner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry 1996, 40:1155-1163.
13. Kovasznay B., Fleischer J., Tanenberg-Karant M., Jandorf L., Miller A.D., Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophrenia Bulletin 1997, 23:195-201.
14. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 2003, 160:1396-1404.
15. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 1994, 51:273-279.
16. McEvoy J., Freudenreich O., McGee M., VanderZwaag C., Levin E., Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry 1995, 37:550-552.
17. McEvoy J.P., Freudenreich O., Wilson W.H. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biological Psychiatry 1999, 46:125-129.
18. Potvin S., Stip E., Roy J.Y. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Canadian Journal of Psychiatry 2004, 49:711.
19. Robinson D., Woerner M., Schooler N. Intervention research in psychosis: issues related to clinical assessment. Schizophrenia Bulletin 2000, 26:551-556.
20. Robinson D.G., Woerner M.G., Napolitano B., Patel R.C., Sevy S.M., Gunduz-Bruce H., Soto-Perello J.M., Mendelowitz A., Khadivi A., Miller R., McCormack J., Lorell B.S., Lesser M.L., Schooler N.R., Kane J.M. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. American Journal of Psychiatry 2006, 163:2096-2102.
21. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., McGorry P.D., Van Hove I., Eerdekens M., Swyzen W., De Smedt G. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. American Journal of Psychiatry 2005, 162:947-953.
22. Sevy S., Robinson D.G., Holloway S., Alvir J.M., Woerner M.G., Bilder R., Goldman R., Lieberman J., Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatrica Scandinavica 2001, 104:367-374.
23. van Nimwegen L.J., de Haan L., van Beveren N.J., van der Helm M., van den Brink W., Linszen D. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Canadian Journal of Psychiatry 2008, 53:400-405.
24. Wade D., Harrigan S., Edwards J., Burgess P.M., Whelan G., McGorry P.D. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry 2006, 189:229-234.